Suppr超能文献

对 2019 新型冠状病毒刺突蛋白与人血管紧张素转换酶 II 相互作用的抑制作用。

Inhibitory Efficacy of Main Components of on the Interaction between Spike Protein of SARS-CoV-2 and Human Angiotensin-Converting Enzyme II.

机构信息

Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu 30068, Taiwan.

Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Linkou, Taoyuan 333423, Taiwan.

出版信息

Int J Mol Sci. 2024 Mar 2;25(5):2935. doi: 10.3390/ijms25052935.

Abstract

Blocking the interaction between the SARS-CoV-2 spike protein and the human angiotensin-converting enzyme II (hACE2) protein serves as a therapeutic strategy for treating COVID-19. Traditional Chinese medicine (TCM) treatments containing bioactive products could alleviate the symptoms of severe COVID-19. However, the emergence of SARS-CoV-2 variants has complicated the process of developing broad-spectrum drugs. As such, the aim of this study was to explore the efficacy of TCM treatments against SARS-CoV-2 variants through targeting the interaction of the viral spike protein with the hACE2 receptor. Antiviral activity was systematically evaluated using a pseudovirus system. () was found to be effective against SARS-CoV-2 infection, as it mediated the interaction between the viral spike protein and the hACE2 protein. Moreover, the active molecules of were identified and analyzed. Baicalein and baicalin, a flavone and a flavone glycoside found in , respectively, exhibited strong inhibitory activities targeting the viral spike protein and the hACE2 protein, respectively. Under optimized conditions, virus infection was inhibited by 98% via baicalein-treated pseudovirus and baicalin-treated hACE2. In summary, we identified the potential SARS-CoV-2 inhibitors from that mediate the interaction between the Omicron spike protein and the hACE2 receptor. Future studies on the therapeutic application of baicalein and baicalin against SARS-CoV-2 variants are needed.

摘要

阻断 SARS-CoV-2 刺突蛋白与人类血管紧张素转换酶 II(hACE2)蛋白的相互作用是治疗 COVID-19 的一种治疗策略。含有生物活性产物的中药(TCM)治疗可以缓解重症 COVID-19 的症状。然而,SARS-CoV-2 变体的出现使得广谱药物的开发变得复杂。因此,本研究旨在通过靶向病毒刺突蛋白与 hACE2 受体的相互作用来探索 TCM 治疗对 SARS-CoV-2 变体的疗效。抗病毒活性使用假病毒系统进行了系统评估。()被发现对 SARS-CoV-2 感染有效,因为它介导了病毒刺突蛋白与 hACE2 蛋白之间的相互作用。此外,还鉴定和分析了的活性分子。黄芩素和黄芩苷,分别是中的一种黄酮和黄酮糖苷,分别针对病毒刺突蛋白和 hACE2 蛋白表现出强烈的抑制活性。在优化条件下,黄芩素处理的假病毒和黄芩苷处理的 hACE2 可抑制 98%的病毒感染。总之,我们从介导奥密克戎刺突蛋白与 hACE2 受体相互作用的中鉴定出潜在的 SARS-CoV-2 抑制剂。需要进一步研究黄芩素和黄芩苷对 SARS-CoV-2 变体的治疗应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97cf/10932139/a5be4926d712/ijms-25-02935-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验